Improving the Diagnosis and Treatment of Early Gastric Cancer in the West.
Endoscopic submucosal dissection
Gastric cancer
Narrow-band imaging
Quality of life
Virtual chromoendoscopy
Journal
GE Portuguese journal of gastroenterology
ISSN: 2341-4545
Titre abrégé: GE Port J Gastroenterol
Pays: Switzerland
ID NLM: 101685861
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
07
05
2021
accepted:
02
10
2021
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Gastric cancer is the third leading cause of cancer-related death. In Western countries, its lower prevalence and the absence of mass screening programmes contribute to late diagnosis and a slower implementation of minimally invasive treatments. A secondary prevention strategy through endoscopic surveillance of patients at high risk of intestinal-type gastric adenocarcinoma or by screening gastric cancer within colorectal screening programmes is cost-effective in intermediate-risk countries, though the identification of these patients remains challenging. Virtual chromoendoscopy with narrow-band imaging improves the accuracy of endoscopic diagnosis, significantly increasing the sensitivity for intestinal metaplasia while preserving specificity. Endoscopic grading of gastric intestinal metaplasia is feasible, correlates well with histological staging systems and also with gastric neoplasia risk and can be used to stratify risk. Endoscopic submucosal dissection (ESD) in the West achieves efficacy and safety outcomes similar to those reported for Eastern countries, and the long-term disease-specific survival is higher than 95%. A prospective comparative study with gastrectomy confirms its higher safety and its benefits concerning health-related quality of life. However, ESD is associated with a 5% risk of postprocedural bleeding and a 20% risk of non-curative resection. The knowledge of risk factors for adverse events and non-curative resection can improve patient selection. The risk of metachronous lesions after ESD is high (3-5% per year), and endoscopic surveillance is needed. The management of patients with non-curative resection can be optimized using risk scoring systems for lymph node metastasis. O cancro gástrico é a terceira causa de morte por cancro. Nos países Ocidentais, a sua menor prevalência e a ausência de programas de rastreio contribuem para o diagnóstico tardio e para uma implementação mais lenta de tratamentos minimamente invasivos. Estratégias de prevenção secundária através da vigilância de indivíduos em maior risco de adenocarcinoma gástrico tipo intestinal ou de rastreio de cancro gástrico (enquadradas em programas de rastreio do cancro colo-retal) é custo-efetiva em países de incidência intermédia, apesar de a identificação destes indivíduos permanecer desafiante. A cromoendoscopia virtual com
Autres résumés
Type: Publisher
(por)
O cancro gástrico é a terceira causa de morte por cancro. Nos países Ocidentais, a sua menor prevalência e a ausência de programas de rastreio contribuem para o diagnóstico tardio e para uma implementação mais lenta de tratamentos minimamente invasivos. Estratégias de prevenção secundária através da vigilância de indivíduos em maior risco de adenocarcinoma gástrico tipo intestinal ou de rastreio de cancro gástrico (enquadradas em programas de rastreio do cancro colo-retal) é custo-efetiva em países de incidência intermédia, apesar de a identificação destes indivíduos permanecer desafiante. A cromoendoscopia virtual com
Identifiants
pubmed: 36159192
doi: 10.1159/000520529
pii: pjg-0029-0299
pmc: PMC9485920
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
299-310Informations de copyright
Copyright © 2021 by Sociedade Portuguesa de Gastrenterologia Published by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors do not have conflicts of interest to disclose.
Références
Gastric Cancer. 2017 Jul;20(4):679-689
pubmed: 27722825
PLoS One. 2015 Nov 10;10(11):e0142080
pubmed: 26556485
Cochrane Database Syst Rev. 2015 Jul 22;(7):CD005583
pubmed: 26198377
Gastrointest Endosc. 2016 Oct;84(4):572-86
pubmed: 27345132
United European Gastroenterol J. 2018 Mar;6(2):192-202
pubmed: 29511549
J Clin Gastroenterol. 2016 Mar;50(3):190-7
pubmed: 26844858
Surg Oncol Clin N Am. 2002 Apr;11(2):235-56
pubmed: 12424848
Gastrointest Endosc. 1993 Jan-Feb;39(1):58-62
pubmed: 8454147
Gut Liver. 2014 Sep;8(5):519-25
pubmed: 25228976
Gastroenterology. 2008 Apr;134(4):945-52
pubmed: 18395075
Endoscopy. 2012 Mar;44(3):236-46
pubmed: 22294194
World J Gastrointest Endosc. 2014 Nov 16;6(11):555-63
pubmed: 25400870
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):700-13
pubmed: 24618998
Aliment Pharmacol Ther. 2012 Jun;35(12):1451-9
pubmed: 22548492
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Gastric Cancer. 2009;12(3):148-52
pubmed: 19890694
Dig Dis Sci. 2010 May;55(5):1364-75
pubmed: 19629687
Gastrointest Endosc. 1999 Oct;50(4):560-3
pubmed: 10502182
Kurume Med J. 2004;51(1):9-14
pubmed: 15150895
BMC Gastroenterol. 2004 Oct 27;4:28
pubmed: 15509297
Endosc Int Open. 2017 Jul;5(7):E563-E572
pubmed: 28670612
Endoscopy. 2016 Aug;48(8):723-30
pubmed: 27280384
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1420-5
pubmed: 27317852
Endoscopy. 2019 Jan;51(1):30-39
pubmed: 29969807
World J Gastroenterol. 2019 Feb 21;25(7):777-788
pubmed: 30809079
Surg Endosc. 2011 Aug;25(8):2666-77
pubmed: 21424201
BMJ. 2015 Jul 27;351:h3867
pubmed: 26215280
Gastroenterology. 1995 Mar;108(3):917-24
pubmed: 7875496
J Gastroenterol. 2017 Feb;52(2):175-184
pubmed: 27098174
Endoscopy. 2019 Jun;51(6):515-521
pubmed: 30577062
Cancer Res. 1988 Jul 1;48(13):3554-60
pubmed: 3288329
Am J Gastroenterol. 2017 Jun;112(6):874-881
pubmed: 28397873
Gastric Cancer. 2018 Jul;21(4):579-587
pubmed: 29460004
Gastrointest Endosc. 2016 Oct;84(4):628-638.e1
pubmed: 26996290
Gastrointest Endosc. 2016 Oct;84(4):618-24
pubmed: 26995689
Gut. 2020 Oct;69(10):1762-1768
pubmed: 32051208
Endoscopy. 2019 Apr;51(4):365-388
pubmed: 30841008
Gut. 2001 Feb;48(2):225-9
pubmed: 11156645
Fam Cancer. 2012 Sep;11(3):363-9
pubmed: 22388873
J Clin Pathol. 2004 Feb;57(2):177-82
pubmed: 14747445
Helicobacter. 2018 Aug;23(4):e12493
pubmed: 29911329
Scand J Gastroenterol. 2016;51(4):501-6
pubmed: 26506982
J Gastroenterol Hepatol. 2016 May;31(5):953-8
pubmed: 26630310
Gastrointest Endosc. 2012 Oct;76(4):763-70
pubmed: 22884100
Best Pract Res Clin Gastroenterol. 2016 Oct;30(5):735-748
pubmed: 27931633
Endoscopy. 2015 Sep;47(9):829-54
pubmed: 26317585
Gastrointest Endosc. 2009 Feb;69(2):350-5
pubmed: 19185696
Gastric Cancer. 2000 Dec;3(4):219-225
pubmed: 11984739
Endoscopy. 2003 Nov;35(11):946-50
pubmed: 14606018
Acta Med Port. 2015 Nov-Dec;28(6):684-6
pubmed: 26849750
Eur J Gastroenterol Hepatol. 2014 Apr;26(4):378-87
pubmed: 24569821
Int J Cancer. 2015 Jan 15;136(2):487-90
pubmed: 24889903
GE Port J Gastroenterol. 2017 Jan;24(1):31-39
pubmed: 28868336
Surg Endosc. 2012 Dec;26(12):3584-91
pubmed: 22678176
Eur J Gastroenterol Hepatol. 2019 Oct;31(10):1234-1246
pubmed: 31498283
N Engl J Med. 1956 Apr 5;254(14):641-4
pubmed: 13309650
Gastric Cancer. 2018 Jan;21(1):114-123
pubmed: 28224238
Gastric Cancer. 1998 Dec;1(1):10-24
pubmed: 11957040
Eur J Gastroenterol Hepatol. 2019 Apr;31(4):418-424
pubmed: 30694909
Gastrointest Endosc. 1990 Sep-Oct;36(5):544-5
pubmed: 2227346